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Introduction:
The current obstetric practice is not to withdraw opiate addicted pregnant women during pregnancy 1 . This recommendation states that opiate detox during pregnancy is associated with an increased risk for stillbirth, fetal distress, premature labor and a high rate of relapse 1 . The fetal concerns primarily stem from two 1970's case reports that suggested fetal harm from detox [2] [3] .
Several studies since these two publications have reported on detox during pregnancy with minimal fetal harm identified [4] [5] [6] [7] [8] .
Opiate addiction in Appalachia has greatly increased over the past 5 years and is at epidemic proportions in East Tennessee 9 . As expected, neonatal abstinence syndrome (NAS) is also at all time highs. In Tennessee, nearly 1000 neonates are treated for NAS at a cost of more than $60 million annually 10, 11 . Because of these healthcare concerns, our institution has actively promoted opiate detox during pregnancy over the past 5 to 6 years.
The primary study purpose was to evaluate the safety of opiate detox during pregnancy due to continued concern that this process may be harmful to the fetus. A secondary study purpose was to assess the rate of delivering a neonate that was treated for NAS.
Materials and Methods:
This study was a retrospective analysis of data collected prospectively during ongoing prenatal care of opiate addicted pregnant women managed by the maternal-fetal medicine (MFM) department at University of Tennessee Medical Center, Knoxville. Data were evaluated for fetal complications of intrauterine fetal demise (IUFD), fetal distress, and preterm labor leading to delivery in pregnancies that underwent detoxification of opiate addiction during pregnancy. Four different methods occurred but were not specifically compared to each other because there was no randomization and the treatment methods varied due to circumstances that
could not be controlled. Group 1 consisted of incarcerated patients. These pregnant women underwent acute detox involuntarily because the jail program in East Tennessee has no ability to provide opiates to prevent or perform an opiate assisted medical withdrawal. The physician that oversees the incarcerated patients can treat symptoms of withdrawal with antiemetic agents, antidiarrheal drugs, and clonidine but no opiates are provided. Furthermore, fetal monitoring is also not available and was not performed during the detox process, though fetal heart tones were intermittently auscultated. These patients did have excellent prenatal follow-up (while incarcerated) since the jail system assured the scheduling of office visits and provided guaranteed transportation to and from appointments. However, if the patient was released from incarceration prior to delivery, responsibility for prenatal care visits would fall back on the patient and missed appointments would occur in some cases but all patients were still delivered by the MFM group.
The second and third groups went through an inpatient drug detox program that uses buprenorphine and fully detoxes the patient in 5 to 8 days treating other physical symptoms as they develop. The majority of these patients (> 90%) were addicted to prescription opiates (such as oxycodone, oxymorphone, and hydrocodone) obtained through diversion. When admitted, they would be treated with buprenorphine and then rapidly tapered. Again, fetal monitoring was not performed during the process, but heart tones were intermittently auscultated. Once fully detoxed, which occurred in every case, an attempt is made to place the patient in an intense behavioral health program that involves either a home that allows for the patient to stay (with her children) that is monitored daily or a daily 8-hour program that the patient participates in Monday through Friday. These inpatient detoxed patients that have intense behavioral health follow-up make up Group 2. Unfortunately, the available spaces for these intense behavioral
health programs are greatly limited and many patients cannot be accommodated. Thus, inpatient detox patients that are not followed with intense outpatient follow-up management make up Group 3.
The fourth group involves the outpatient slow buprenorphine detox program, which is performed by a few clinics in the East Tennessee area that will stabilize the patient on a maintenance dose and then slowly taper them down to zero over 8 to 16 weeks depending on the motivation of the patient and the gestational age of the pregnancy. Once fully detoxed, these patients are maintained in continued behavioral health follow-up.
Because the study purpose was to evaluate the safety of opiate detox during pregnancy, only patients that were fully detoxed were included. All of the patients in Groups 1, 2 and 3 were fully detoxed based on the process of their grouping. Some of the patients that were managed in the outpatient buprenorphine group were not successful at becoming fully detoxed and these unsuccessful patients are part of another ongoing study. To make the assessments equal between the Groups, only those that completely detoxed in this outpatient group were included and make up Group 4. No other exclusion criteria were included. For definition purposes, the trimester for when detoxification occurred was defined based on when the process was fully completed and was easily demarcated for Groups 1, 2, and 3 due to the short duration. For Group 4, because the detoxification process occurred over a period weeks, some patients may have begun detoxification in an earlier trimester.
For the secondary study objective, the incidence of delivering a neonate that was treated for NAS was also collected for each method to determine if there was any difference in effectiveness at minimizing this condition for the newborn. Relapse rates for all of the study patients were analyzed and relapse was defined as a positive drug screen on admission, an
admission by the patient at the time of delivery that she had relapsed, or a positive neonatal meconium test. NAS is a reportable condition to the State of Tennessee Health Department.
Every newborn at our medical center that is delivered of a mother who is or was taking opiates during the pregnancy, either by history or by positive drug screen on admission, is followed by the neonatal intensive care physicians for 3 to 5 days. Student t-test where applicable and p < 0.05 was considered significant.
Results:
A total of 301 opiate addicted pregnant patients were fully detoxed during pregnancy with no adverse fetal outcomes related to detox identified. Demographics are seen at the top of Table 1 . There were no differences in mean maternal age, maternal age range, or the number of patients under the age of 30. However, as depicted, 3 out of 4 patients were under 30 years of age consistent with what has previously been reported 9 . The majority of patients in each Group were multiparous with a 78% rate for the entire study population. Group 1 had a statistically higher number of multiparous patients when compared to Groups 2 & 3 at P =.008. Additionally, 88%
of the entire study population was Caucasian. There were a statistically higher number of African-Americans in Group 1 compared to the other groups (p < 0.01).
The mid portion of Table 1 depicts the gestational age at the time of detoxification and the admission rate to the NICU. Of the 301 patients, there were 28 detoxed in the first trimester from 5 through 13 weeks gestation. Two IUFD's occurred in this group and both were patients acutely detoxed. One involved a patient that was acutely detoxed at 10 weeks gestation but had an IUFD at 18 weeks gestation with a placental abruption. She was still incarcerated and her drug screen at the time of the loss was negative. The second was also acutely detoxed at 12
weeks gestation and was found to have an IUFD at 34 weeks gestation of a fetus with hydropic changes. Autopsy was declined and her drug screen and testing were all negative at the time of diagnosis as well. There were 148 detoxed in the second trimester from 14 weeks through 27 weeks and 125 detoxed in the third trimester from 28 weeks gestation and greater with no episodes of IUFD. There were no cases of preterm premature rupture of membranes or preterm delivery that occurred during the process of detoxification.
Regarding the rate of treatment for NAS (seen at the bottom of Table 1 ), 94 patients (31%) overall delivered a neonate that was treated for NAS. Of the 301 patients, 108 were acutely detoxed while incarcerated (Group 1 patients) and 20 cases of NAS occurred following delivery for a rate of 18.5%. There were 100 patients that were detoxed as an inpatient with 23 that were placed in long-term follow-up behavioral health programs following the detox (Group Table 1 also depicts the numbers of women in each group that relapsed back to taking opiates as defined. As shown, relapse is higher than the rate of treatment for NAS for each group because there were some that relapsed as defined but the neonates did not experience NAS.
Excluding Group 1 patients that were acutely detoxed following incarceration, Group 2 and Group 4 patients combined represent those that were fully detoxed and remained in longterm behavioral health settings. The rate of NAS in this combination was 20 in 116 or 17.2%. If this is compared with Group 3 (those detoxed and managed without intense outpatient follow-up management) with a rate of 54 in 77 or 70.1% the difference is highly significant at p < .0001.
The overall delivery rate prior to 37 weeks gestation (53 patients) is somewhat high at 17.6%, but 28 of these (53%) were inductions of labor for a diagnosis of severe intrauterine growth restriction. Interestingly, at the time of delivery, the fetal weight was < 5% in only 16 of the 28 (57%). The preterm delivery rates were no different based on when detoxification occurred. Likewise, 40% of the newborns were admitted to the NICU, but this includes the 31% treated for NAS. The remaining 9% primarily included admissions for prematurity or for extended observation for signs of NAS.
Comment:
Principal findings:
These data highly suggest that detoxification from opiates during pregnancy is not harmful. Additionally, the rate of treatment for neonatal abstinence syndrome is less if long-term M A N U S C R I P T
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Meaning of our observations as it relates to other studies:
The standard of care for more than 35 years in obstetrics has been to take opiate addicted pregnant patients and place them in a methadone maintenance program. More recently, buprenorphine maintenance has also been recommended as another treatment option for this population 1 . The concern for opiate detoxification during pregnancy has largely been a safety issue for the fetus. Other reported concerns involve a high rate of relapse following detox and better prenatal care follow-up for the patients in the maintenance programs 1,7 .
The fetal concerns are primarily based on 2 cases reports from the 1970's. Rementeria and Nunag in 1973 reported a stillbirth that occurred in a patient who had withdrawal symptoms shortly before delivery at 39 weeks gestation 2 . This publication also discussed the varying data in the literature from the preceding 10 years regarding stillbirth and meconium stained amniotic fluid in drug-addicted pregnancies. The author's conclusion was that many of these detoxed women relapse and due to a greater risk of withdrawal, methadone maintenance programs should be encouraged. The second case report was from Zuspan et al in 1975 3 . This study reported on elevated levels of epinephrine and norepinephrine (suggesting fetal stress) obtained during serial amniotic fluid assessments over a 10-week period from a patient being detoxed from methadone during the pregnancy. Thus, opiate detoxification during pregnancy was not recommended. patients that elected to undergo inpatient methadone detox during a 6-year period and 53 (56%)
were successful 8 . The rate of NAS in the detox group was 10% compared with 80% in the patients that were not successful and this difference was significant at p < .001. There were no cases of fetal demise and no cases had fetal distress during the detoxification process.
Our primary study purpose was to determine if full detoxification from opiates during pregnancy was harmful to the fetus. With our 301 study patients and the patients reported in these 5 follow-up studies, more than 600 patients have undergone detox during pregnancy with no report of IUFD or preterm delivery related to the process.
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The secondary study question involved the rates of NAS treatment in each of the groups.
No study including this report has found an absence of NAS in the delivered newborns of mothers that were fully detoxed. All of the newborns treated for NAS in our study came from mothers that had relapsed. This included the 4 patients in Group 2 that were living in a behavioral health home or seen on a daily basis. This confirms that treating addiction is difficult and failures will occur, whether it is alcohol, tobacco, or opiates. Furthermore, relapse rates are high in nearly all of the studies to date. However, our data demonstrate that relapse can be substantially reduced if detoxed pregnant women are followed in intense behavioral health programs once they become drug free.
Clinical and research implications:
An important question involves long term outcomes for neonates born of drug addicted mothers. Currently, there are no long-term follow-up studies on newborns delivered of mothers that were detoxed during pregnancy and this warrants further evaluation. There are studies that have evaluated long-term outcome in infants born of drug addicted mothers including those on methadone, but it is always difficult to know how much effect is related to the in-utero drug exposure versus the lifestyle these children grow up in 13, 14 .
At the present time, if a pregnant patient is found to be addicted to opiates, she is most likely to be referred to a methadone maintenance program, a process whereby the opiate intake is managed by the maintenance program while prenatal care is performed by the obstetrical provider. For detoxification during pregnancy, if the process is to remain similar, systems would need to be developed, such that the opiate addicted pregnant woman is referred to the drug detox/long term behavioral health program for drug management and the prenatal care would occur with the obstetrical provider. These drug detox/long term behavioral health programs M A N U S C R I P T
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14 currently do not exist nationwide and therefore, would need to be created and funded if any success is expected. Nevertheless, the cost of treating one neonate for NAS in the state of Tennessee is about $63,000 as of 2011 10 . In Tennessee, nearly 1000 newborns are treated for NAS leading to a healthcare cost of more than $60 million annually for the State 11 . Therefore, developing and providing long-term behavioral health for pregnant women once they are successfully detoxed will require funding, but the cost savings on decreasing the number of newborns treated for NAS would easily overshadow these expenses.
Strengths and Limitations:
The strength of this study is the large number of patients fully detoxed during pregnancy through different processes that could also assess the rate of NAS based on the method of detox.
This study, however, has several limitations. Due to the sensitive nature of drug addiction during pregnancy, in order to obtain approval from the jail system, the inpatient detox program, and the institutional review board, once the collected data was analyzed, all patient identification had to be removed from the database. Thus, no further information or further follow-up of patients can take place. Secondly, this process cannot be instantly incorporated into routine prenatal care since it has taken an extensive period of time to develop outpatient detox and long-term behavioral health programs in East Tennessee and this will likely take time in other areas of the country if the decision is made to begin a similar program. Third, the incarcerated patients are unique in this study and this process will not likely be extrapolated to routine prenatal care.
These patients however can be used to show that acute detox during pregnancy does not result in a large number of poor outcomes, which was the primary goal of this study. Unfortunately, the timing of when patients were released from jail could not be accurately obtained to make any conclusion on rate of relapse once these patients were no longer incarcerated. Fourth, our M A N U S C R I P T
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buprenorphine population is also different in that some who attempt complete detox, do not fully succeed. However, because those in the jail and those detoxed as an inpatient were all drug free at a given point in time during the pregnancy, we only included buprenorphine patients that were completely drug free at a given point in time during the pregnancy. Those that were maintained on some amount of buprenorphine are being evaluated separately to see if there is a dosage level whereby the risk of NAS is minimal. A fifth limitation is that complete safety of detox in the first trimester cannot be addressed with our data due to small numbers. Intrauterine fetal demise occurs in all groups of pregnant patients, including the low risk population 15 , and an IUFD will eventually occur in an opiate addicted pregnant patient that undergoes detox, but these data do not suggest that the process of detox would be the cause.
Conclusion:
In conclusion, detox of opiate addicted pregnant women does not appear to be harmful. In addition, the rate of NAS can also be reduced if continued long-term behavioral health follow-up occurs once a patient is drug free.
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